• Arcutis Biotherapeutics held its annual shareholder meeting on June 5, 2026.
• Shareholders backed the slate of Class III director nominees; the outcome authorizes board appointments, not any subsequent board actions.
• Ernst & Young was ratified as independent auditor for the fiscal year ending Dec. 31, 2026; the vote supports the appointment, not the audit work.
• Separately, the board adopted revisions to the amended and restated non-employee director compensation program, effective as of the meeting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcutis Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-041883), on June 09, 2026, and is solely responsible for the information contained therein.